JN's Quality Control & Research Laboratory
Over the past 15 years, new Neurological therapy candidates were placed into development, with 2 advancing to pre-clinical trials. The majority of these have the potential to be ﬁrst- or best-in-class preventive and therapies for Transient Ischemic Stroke and Alzheimer's .
JN’s research and development organization draws upon expertise in multiple discovery platforms. This means that, in addition to traditional small molecules, we are sharply focused on biologics. We have outlined a number of early-stage development that include three novel CNS vaccines and diagnostics to ﬁght Stroke and Alzheimer’s diseases. We also have programs progressing through development that seek to expand existing products with newly identiﬁed uses and indications. We are hopeful for U.S. approval in 2017 for Meningococcal conjugate vaccine and our human trial outcome will be reviewed at an FDA advisory committee meeting.
Type 2 (HSV-2) is a suitable target for a vaccine, despite available antiviral therapies, because the virus causes lifelong infection and significant medical and psychosocial morbidity.
GH non-IND Phase-1 non-IND Study: This study has been initiated in Cambodia using Herpes infected and control subjects.
This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers in South Africa.